{"meshTagsMajor":["Clinical Trials as Topic"],"meshTags":["Humans","Clinical Trials as Topic","Proto-Oncogene Proteins B-raf","Protein Kinase Inhibitors","Melanoma","Structure-Activity Relationship","Molecular Weight"],"meshMinor":["Humans","Proto-Oncogene Proteins B-raf","Protein Kinase Inhibitors","Melanoma","Structure-Activity Relationship","Molecular Weight"],"genes":["BRAF"],"publicationTypes":["Journal Article","Review"],"abstract":"Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.","title":"Small molecule inhibitors of BRAF in clinical trials.","pubmedId":"22222036"}